MD ANDERSON SURGICAL ONCOLOGY HANDBOOK 5TH EDITION PDF
Since the inception of the first edition of The MD Anderson Surgical Oncology Handbook, the field of Surgical Oncology has witnessed substantial advances. i. FIFTH EDITION. The MD Anderson Surgical Oncology Handbook Editors Barry W. Feig, MD C. Denise Ching, MD MD Anderson Cancer Center Department of. The sixth edition of the. MD Anderson Surgical Oncology Handbook focuses on multidisciplinary, cooperative approaches to issues confronting the surgical.
|Language:||English, Spanish, Indonesian|
|Genre:||Business & Career|
|ePub File Size:||23.75 MB|
|PDF File Size:||17.26 MB|
|Distribution:||Free* [*Regsitration Required]|
M.D. Anderson Surgical Oncology Handbook, The View PDF. M.D. Anderson Surgical Oncology Handbook, The. Publication Year: Edition: 6th Ed. The MD Anderson Surgical Oncology Handbook, Fifth Edition. Article in Annals of Surgery Request Full-text Paper PDF. Citations (1). References (0). Request PDF on ResearchGate | On Apr 1, , Neal Wilkinson and others published The M.D. Anderson Surgical Oncology Handbook, 4th Edition.
Ryan M. Mark J. Ara A. Gauri R. Mark T. Judith K. Christopher G. Since the publication of the first edition, the field of surgical oncology, the surgical care of patients with cancer, has grown from an avocation practiced by a few committed surgeons, usually trained in general surgery, to a defined and vigorous specialty with its own subspe- cialties, including those of breast, colorectal, melanoma, sarcoma, and hepatobiliary surgery.
Since the first edition of The Handbook, there have been major advances that have transformed the field. These have included advances in surgical techniques that have minimized patient morbidity and at the same time allowed refinement in surgical indications.
Such advances have included the introduction of sentinel lymph node biopsy, especially for patients with melanoma and breast cancer; and advances in mini- mally invasive surgery, initially in the staging and palliative treatment of patients with gastrointestinal malignancies but now established as a standard of care for selected patients with various early-stage tumors, including colon cancer and adrenal tumors.
Advances have also included technical innovations, including in liver, pancreatic, peritoneal, soft tis- sue, and reconstructive surgery that have allowed surgical care to be extended to patients not previously considered surgical candidates, including patients with bilobar liver tumors, those with involvement of major abdominal vasculature, and carcinomatosis.
Major prog- ress in our understanding of the molecular biology and the natural his- tory of many solid tumors, through investigations often led by surgical oncologists, have resulted in a much deeper and more profound under- standing of the mechanisms responsible for cancer incidence and pro- gression.
These advances have led not just to more accurate staging of patients with these cancers but to more accurate selection of patients for surgical treatment, and in some cases more effective and less toxic systemic therapies. Finally, integration of cancer-specific diagnostic.
The current edition of The Handbook provides an overview of cur- rent care of patients with cancer diagnoses commonly evaluated and treated by surgical oncologists and in doing so continues to align such care with the underlying philosophy of the Department of Surgical Oncology at MD Anderson: Such care begins with an understanding of the underlying tumor biology and natural history of the disease and includes technical excellence in the delivery of indicated surgical treatment.
It also demands integration of essential information from the available literature on currently preferred treatment modalities and emphasizes appropriate inclusion of adjunctive specialty care, including medical oncology, radiation oncology, interventional radiol- ogy, palliative care, pain management, physical therapy, nutritional sup- port, social services, and nursing. I am confident that you will find the current edition of The Hand- book useful, whether you are a medical student on a surgical rotation, a surgical resident, a surgical oncology fellow, or an interested specialist in a related discipline.
Especially for those of you early in your training, I hope that your exposure to the exciting and deeply rewarding field of surgical oncology through your surgical rotations and this handbook will interest some of you in pursuing the surgical care of patients with cancer as a career.
I am delighted to be able to introduce the current edition of The Handbook to you and honored to have been a small part of it since the first edition.
The dynamic nature of the field of surgical oncology will demand that we continue to revise and update its con- tents; it is exciting to know that some of you reading this will contribute to future editions! The concept for the MD Anderson Surgical Oncology Handbook was origi- nally conceived 16 years ago with the original objective being an attempt to document the philosophies and practices of the Department of Surgi- cal Oncology at the MD Anderson Cancer Center.
Since that time, through four editions, the book has become a practical guide for resi- dents, fellows, and attending staff, to the established surgical oncology principles for treating cancer as it involves each organ system in the body.
The purpose of the book is to outline management approaches based on our experience with surgical oncology problems at MD Anderson. Consistent with the original concept, this book is written by current and former surgical oncology fellows at MD Anderson. Although the tar- get audience for the first edition was surgical house staff and surgical oncology trainees, we found that there was a significantly wider appeal for the book across multiple disciplines and at various levels of training and experience.
The handbook continues to maintain this appeal, despite various subsequent publications of similar intent, within other specialties. The authors represent various disciplines within oncology and training programs, and they have spent at least 2 years at the MD Anderson Cancer Center studying only surgical oncology. The diversity of authors allows us to present the current opinions and practices of the MD Anderson Department of Surgical Oncology, along with other opin- ions and treatment options practiced in a wider range of surgical train- ing programs.
By maintaining the emphasis of the book from the perspective of the surgical oncology fellows, we hope to prevent the book from becoming overly dogmatic in our medical opinions and prac- tices. This handbook is not meant to encompass all aspects of oncology in minute detail. Rather, it is an attempt to address commonly encoun- tered as well as controversial issues in surgical oncology.
While other authors present their opinions and approaches as firmly established, we have tried to point out controversies and show alternative approaches to these problems besides our own. We particularly thank the patients seen and treated at MD Ander- son for their warmth and appreciation of our care, as well as for their patience and understanding of the learning process.
We are all aware that there is still a significant amount of learning that we all must entail in order to achieve our mission of eradicating cancer. Mansfield Fleming Cary Hsu. Primary Gastric Malignancies Maria C. Kelly Herne. Soft-tissue and Bone Sarcoma Abigail S.
Robert H. Vaporciyan 8. Cancers of the Head and Neck Kenneth A. Melanoma 85 Joshua M. Cancer of the Colon. Denise Ching 3. Yi-Qian Nancy You. Hofstetter 9. Cormier 6. Cormier 5. Invasive Breast Cancer 27 David S. Newkirk and F. Noninvasive Breast Cancer 1 Priscilla F. Christopher Holsinger 7.
Esophageal Carcinoma Wayne L. Hunt 2. Sharon R. Nonmelanoma Skin Cancer Melinda M. Thoracic Malignancies Shanda H. Blackmon and Ara A. Gershenwald 4. Romaguera Genitourinary Cancer Jose A. Hepatobiliary Cancers Carlo M.
Wolf Targeted Cancer Therapy Mark J. Lee Pancreatic Adenocarcinoma Debashish Bose. Robb Grubbs McCutcheon Karam and Christopher G. Wood Abdalla Neurosurgical Malignancies: Treating Tumors of Brain. Gynecologic Cancers Liz Y.
Truty Landry and Jeffrey E. Abad and Jorge A. Principles of Radiation Oncology Christopher Crane Varadhachary The median age reported for patients with DCIS ranges from 47 to 63 years. The reported prevalence of DCIS has increased as the quality and sensitivity of mammography have improved.
Hunt Noninvasive breast cancer comprises two separate entities: In the United States. DCIS is defined as a proliferation of epithelial cells confined to the mammary ducts.
The inci- dence of detection of DCIS is higher in autopsy studies than in the gen- eral population.. Because they are nonin- vasive. The frequency of a family history of breast cancer among first- degree relatives of patients with DCIS i. Other risk factors for DCIS are the same as those for invasive breast cancer. Silverstein et al. The classification of noninvasive breast cancer stratifies lesions based on their likelihood of recurrence and incorporates prognostic factors.
Malignant cells proliferate until the ductal lumen is obliterated. They arise from ductal epithelium in the region of the terminal ductal—lobular unit. DCIS has been linked with changes in the surrounding stroma resulting in fibroblast prolifera- tion. Although the process is poorly understood. DCIS has traditionally been considered one stage in the continuum of histologic progression from atypical ductal hyperplasia to invasive carcinoma. Other classification sys- tems have been proposed.
At 8 years. DCIS comprises a heterogeneous group of lesions with variable histologic architecture. Cribri- form. Lagios et al. DCIS does not have the ability to metastasize to axillary lymph nodes or distant sites. By definition. The incidence of microinvasion in DCIS varies according to the size and extent of the index lesion.
Mirza et al. Because mammary lobules are not constrained by the artificially imposed quadrant segregations. Most investigators believe that multifocal disease in fact represents intraductal spread from a single focus of DCIS. By careful serial subsectioning. The incidence of microinvasion is also higher in patients with high-grade or comedo-type DCIS with necrosis and in patients with DCIS who present with a palpable mass or nipple discharge.
Holland et al. Mammographic images should be compared with pre- vious images. Mammographic Features On a mammogram. Diagnosis Clinical Presentation Before the implementation of routine screening mammography.
Patients with microinvasion and those with T1 tumors had similar survival rates. In patients with palpable lesions. DCIS with microinvasion. Now that screening mammography is more prevalent. Patients with abnormalities detected by mammography should always undergo imaging of the contralateral breast because 0. The overall survival rate was also better in patients with DCIS DCIS can present as microcalcifications.
In a retrospective study of 1. DCIS was an incidental finding in an otherwise benign breast biopsy specimen.
These results suggest that DCIS with microinvasion should be characterized as a small invasive tumor with a good outcome and that the therapeutic approach for these patients should be similar to that for patients with invasive cancer. The cost and accessibility of magnetic resonance imaging MRI make it less feasible as an effective screening method. There is ongoing research interest in using MRI to predict the presence of invasive disease among patients initially diagnosed with DCIS on core needle biopsy.
MRI is increasingly being utilized after initial diagnosis in the preoperative evaluation to identify multicentric and contralateral lesions.
Of the patients with DCIS. Although the morphology of microcalcifications suggests the architectural type of DCIS.
Hollingsworth et al. Lehman et al. Chapter 1 Noninvasive Breast Cancer 5 a linear branching-type microcalcifications. MRI prompted biopsy in 18 patients. Biopsy specimens should be radiographed to document the sampling of suspicious microcalcifications. Care should be taken to mark the biopsy site with a metallic clip in the event that all microcalcifications are removed with the biopsy procedure.
Patients who are not candidates for stereotactic biopsy or who have stereotactic biopsy results that are inconclusive or discordant with the mammographic findings should undergo excisional biopsy. Specimen radiography is essential to confirm the removal of microcalcifications of interest.
Calcifications that appear faint on mam- mogram or that are deep in the breast and close to the chest wall may be difficult to target with stereotactic biopsy. Because stereotactic core-needle and vacuum-assisted biopsy spec- imens represent only a sample of an abnormality observed on mammog- raphy. In addition. After diagnosis using stereotactic core-needle biopsy. Treatment The diagnosis of DCIS is followed by surgical treatment with a mastec- tomy or breast-conserving surgery also referred to as segmental mastec- tomy.
The excisional biopsy should be performed with the aim of obtaining a margin-negative resection that can serve as a definitive surgery. Patients who cannot remain prone or who cannot cooperate for the duration of the procedure are also not good candidates for stereotactic biopsy.
If the core-needle biopsy results are discordant with the findings of imaging studies. This tech- nique is performed with the assistance of preoperative needle localiza- tion of the mammographic abnormality or of the previously placed metallic clip marking the biopsy site. Bleeding disorders and the concomitant use of anticoagulants are relative contraindications.
The rationale for per- forming total mastectomy in patients with DCIS was based on the high incidence of multifocality and multicentricity. Boyages et al. The cancer-related mortality rate following mas- tectomy for DCIS was 1. In patients who underwent breast-conserving surgery alone. In one of the largest studies comparing breast-conserving therapy with mastectomy.
A retrospective review by Balch et al. Technique of Breast-conserving Surgery The goal of breast-conserving surgery is to remove all suspicious calcifi- cations and obtain negative surgical margins. Mastectomy Versus Breast-conserving Therapy Traditionally. Intraoperative orientation of the specimen with two or more marking sutures is critical for margin analy- sis.
Chapter 1 Noninvasive Breast Cancer 7 improve local control. In a meta- analysis. DCIS was treated with mastectomy. In this nonrandomized study. Although recurrence rates are higher in patients who undergo breast-conserving surgery than in patients who undergo mastectomy. In patients with extensive calcifications. Postoperative endocrine therapy with tamoxifen should also be considered for those patients whose tumors are estrogen receptor positive.
Because DCIS is usually nonpalpable. A detailed pathologic study of DCIS. Lesion size was another predictor of residual DCIS. Three prospective randomized studies have evaluated the role of radiation therapy following breast-conserving surgery for DCIS. After whole-specimen radiography. After the intraoperative margins are deemed adequate. Chagpar et al. Most surgeons advocate re-excision for positive surgical margins. The goal of breast-conserving surgery is to obtain tumor-free mar- gins.
At a follow-up time of 12 years. Neuschatz et al. There was no difference in the year overall survival rate in the two groups. Radiation Therapy Most patients with DCIS who undergo breast-conserving surgery receive postoperative radiation therapy. The lower recurrence rates in this trial when compared with those in the NSABP B were attributed to the shorter follow-up time. Taken together. On the basis of this knowledge. At a median follow-up time of 4.
In this trial. Chapter 1 Noninvasive Breast Cancer 9 3.
The most common morbidity is radiation-induced skin changes including discol- oration. Partial Breast Irradiation In patients not receiving radiation therapy. Whole-breast radiation has been the standard for patients undergo- ing breast-conserving surgery and is generally tolerated well.
Acceler- ated partial breast irradiation is a technique where high-dose radiation is delivered over a shorter period of time to a limited region of the breast surrounding the primary tumor site.
After a median follow-up time of 4. The treatment is completed over 4 to 5 days. A third trial.. The primary endpoint is local tumor control. Patients will receive chemotherapy and endocrine therapy at the discretion of their treating physician. Other patients who are candidates for breast-conserving surgery choose to undergo a mastectomy because of concerns about postirra- diation complications.
Of patients with DCIS enrolled. Of these. The 5-year actuarial locoregional recurrence rate of 3. The rates of radiation therapy use have been shown to vary.
Breast-conserving surgery alone i. Initial data that supported the use of breast-conserving surgery alone in the treatment of DCIS came from a study by Lagios et al. Patients with no more than 3-cm DCIS or invasive stage I or II breast cancer who undergo margin-negative breast-conserving surgery are being randomized to standard adjuvant whole-breast external beam radiation therapy or accelerated partial breast irradiation.
After a follow-up time of months. A size score of 1. Silverstein proposed the following treatment schema for DCIS: In contrast. Chapter 1 Noninvasive Breast Cancer 11 recurrence: The pathological classification is 1 for non—high-grade DCIS without necro- sis.
In a retrospective study of patients with DCIS treated with or without radiation therapy after breast-conserving surgery. In a retrospective analy- sis of patients with DCIS who underwent breast conservation with margins that were at least 10 mm. Margin width is assigned a score of 1 if 10 mm or greater.
[FREE] EBOOK The M.D. Anderson Surgical Oncology Handbook BEST COLLECTION
Numerical values ranging from 1 best prognosis to 3 worst prognosis are assigned for each of the four predictors. Patient age is assigned a score of 1 for greater than 60 years. Wong et al. More recently. The nomogram calculates an actual. Long-term follow-up of this cohort is ongoing. At a median follow-up of 3. Endocrine Therapy Two prospective randomized trials have evaluated the effect of tamoxifen on outcome in patients with DCIS treated with breast-conserving therapy.
At 7 years of follow- up. These include age at diagnosis. The nomogram incorporates commonly available factors which have previously been shown to affect risk of ipsi- lateral breast tumor recurrence. Rudloff et al. There are two large prospective studies designed to investigate the role of observation versus radiation therapy after breast-conserving therapy in patients with DCIS. This trial was closed early due to poor accrual. Sixteen percent of the women in this study had positive resection margins.
Among those who received tamoxifen. The benefit of tamoxifen therapy also extended to patients with positive mar- gins or margins of unknown status. The decision of whether to use adjuvant tamoxifen for patients with DCIS should be made on an individual basis. Houghton et al.
These agents have fewer cardio- vascular side effects than tamoxifen and may be beneficial in the adju- vant treatment of patients with DCIS following breast-conserving surgery. The risk of endo- metrial cancer is increased two to seven times among patients who receive the drug. Tamoxifen is also associated with increased rates of stroke and benign ovarian cysts.
Among patients with estrogen receptor-negative DCIS. Most deaths occurred before recurrence developed and were not necessarily related to breast cancer. Chapter 1 Noninvasive Breast Cancer 13 7-year cumulative incidence of contralateral breast neoplasms invasive and noninvasive to 2. The relatively short follow-up time and complex design of this trial makes interpretation of the results in direct comparison to the NSABP B trial difficult. Aromatase inhibitors have been shown to be beneficial in the adju- vant treatment of invasive breast cancer in postmenopausal women with estrogen receptor-positive disease.
A subgroup analysis. There was no difference in the 7-year overall survival rate. Patients with positive margins were excluded from this trial. The use of tamoxifen has been associated with vasomotor symptoms.
Molecular markers. This risk must be weighed against the risk of lymphedema associ- ated with sentinel node dissection in each patient. As described previ- ously. Such patients are at higher risk for lymph node metastasis. A strong family history of breast cancer is associated with an increased risk of local recurrence.
Patients with large. Traditional pathological variables. Results from these trials have not been reported but will help to define the role of aromatase inhibitors in the adjuvant treatment of DCIS. Involved margins of resection constitute the most important indepen- dent prognostic variable for predicting local relapse.
Klauber- DeMore et al. In a study by Cox et al.
Chapter 1 Noninvasive Breast Cancer 15 heat shock protein. If the recurrent tumor is invasive. Follow-up of patients after breast-conserving surgery with or without radiation therapy should include annual or biannual physical examination and annual mammography for the first 5 years. Whether this improves the detection of recurrence and outcome is not known.
In both trials. For patients who have recurrent breast cancer after receiving breast-conserving surgery and radiation therapy. Although most patients with recurrent disease after DCIS do survive. The National Comprehensive Cancer Network treatment guidelines recommend a physical exami- nation every 6 months for 5 years and annually thereafter.
The management of local recur- rence depends on the therapy the patient received for the primary cancer. In a follow-up study. The prognosis after treatment of local recurrence depends on whether the recurrence is invasive or noninvasive. Patients with DCIS should undergo long-term follow-up for both recurrent disease and development of new ipsilateral or contralateral primary tumors.
Surveillance Following breast-conserving surgery. Romero et al.
In cases of local recurrence in patients who underwent breast-conserving surgery without radiation therapy. Anderson Cancer Center is outlined in Figure 1. Most patients with DCIS are candidates for breast- conserving therapy.
The benefits and risks of breast-conserving surgery and mastectomy should be discussed in detail with each patient. The choice of surgical therapy for an individual patient is based on several factors. Diagnostic biopsy is performed by using a vacuum-assisted stereotactic core-needle biopsy technique. The risk of development of a new primary cancer in the contralateral breast after treatment of DCIS is two to five times greater than the risk of development of a first primary breast cancer and is approximately the same as the risk of development of a new contralateral primary cancer after invasive cancer.
There are few data available on the efficacy of breast-conserving surgery for DCIS with index lesions greater than 4 cm in diameter. Mastectomy is indicated in patients with diffuse. Immediate breast reconstruction should be considered for all patients who require or elect mastectomy.
Mag- nification views are routinely used to delineate the abnormality in the index breast. Ultrasound is also frequently used to assess tumor size. Although tumor size is not an absolute indication for mastectomy. When DCIS is diagnosed. Patients diagnosed with a mam- mographic abnormality undergo bilateral diagnostic mammography. The decision to use MRI is based on the density of the breasts and the findings on mammographic imaging. When available.
No No re-excision? Anderson Cancer Center. During the era that followed. In patients who undergo breast-conserving surgery.
Customers who bought this item also bought
Patients who receive breast-conserving surgery and radiation therapy undergo a diagnostic mammogram after surgery to ensure removal of all suspicious calcifications. All patients with DCIS are considered for clinical trials. Tamoxifen is offered for 5 years to women with estrogen receptor-positive DCIS who do not have a history of venous thromboembolism or stroke. Partial breast irradiation is offered for selected patients. Haagensen et al.
The risk of developing a subse- quent carcinoma was equal for both breasts. If a mastectomy is performed. Adjuvant radiation therapy is recommended to reduce the risk of local recurrence in patients who undergo breast-conserving surgery. Following surgical resection. In a review of cases. Patients who undergo mastectomy for DCIS routinely undergo intraoperative lymphatic mapping and sentinel lymph node dissection. Re-excision is usually recom- mended for patients who have margins less than 2 mm on final patho- logical examination after breast-conserving surgery.
Haagensen concluded that close observation for LCIS allowed for early detection of subsequent malignancy. Molecular analysis of LCIS and invasive lobular carcinoma has revealed decreased expression or loss of the cell surface adhesion molecule E-cadherin in both tumor types.
The increase in incidence in women 40 to 49 years old continued up until but then stabilized. Li et al. Although classic LCIS may not be associated with invasive lobular carcinoma. The theory that LCIS represents a marker of increased risk of inva- sive breast carcinoma is supported by the fact that the mean age at diag- nosis is 10 to 15 years younger than that for invasive cancer. Chapter 1 Noninvasive Breast Cancer 19 However.
Epidemiology The incidence of LCIS is difficult to estimate because the diagnosis is most often made as an incidental finding. Between and On evaluation of mammographic abnormalities. LCIS was more commonly reported in premenopausal women than in postmenopausal women. LCIS is often not detectable by palpation. LCIS is found in 0. The reason for this increase in LCIS seen in women 50 years of age or older is multifactorial.
Increased use of screening mammography led to an increased number of biopsies performed. This contrasts with ductal carcinoma. The cells have a homogeneous morphology and do not display promi- nent chromatin. Papillomatosis in the terminal ducts may resemble LCIS but lacks the characteristic involvement of the acini. These data further strengthen the the- ory that LCIS is not only a marker for increased risk of invasive breast cancer.
LCIS is contained within the basement membrane and is thus distinguished from invasive lobular carcinoma. LCIS and invasive ductal carcinoma have also been shown to exhibit similar loss of heterozygosity. The cytoplasm-to-nucleus ratio is normal.
In the absence of complete replacement of the lobular unit. Fisher et al. Numerous studies have documented that LCIS is multifocal and multicentric. DCIS may extend retrograde into the acini. The cells are slightly larger and paler than those that line the normal acini. As a result. This variant may be more prone to progressing to invasive lobular carcinoma.
The proliferating cells do not penetrate the basement membrane. If diligently sought. Pathology LCIS is characterized by intraepithelial proliferation of the terminal ductal—lobular unit. In another study of patients with LCIS. Nine of 26 Chapter 1 Noninvasive Breast Cancer 21 for fibroadenoma. Ultra- sound is also useful in evaluating suspicious findings.
The free excision margins were believed to have contributed to the low rate of invasive ipsilateral breast tumors. In a study of patients who underwent observation alone after margin-negative surgical excision of LCIS. In this study. In contrast with DCIS.
Only 2 of the patients in the study died from breast cancer. Ottesen et al. In the past. On the other hand. Treatment Surgery The optimal clinical management of patients diagnosed with LCIS iden- tified on core-needle biopsy remains controversial. Ciocca et al. Most of the patients diagnosed with LCIS since the mids have undergone clinical observation alone based on the recommendations of Haagensen.
Patients diagnosed with LCIS should undergo bilateral diagnostic mammography to exclude other abnormalities in the breast. Contralateral mirror-image breast biopsy. The crude local recurrence rate of the patients with LCIS within the specimen 4. Immediate breast reconstruction should be offered for patients who undergo prophylactic mastectomy for LCIS. Vogel et al. Further study of the various LCIS subtypes is needed to determine whether patients with some subtypes would indeed benefit from re-excision.
Ciocca did not recommend re-excision if LCIS was identified at or close to margin sur- faces and concluded that LCIS was likely not a precursor to the develop- ment of invasive lesions. A viable therapeutic option for LCIS is bilateral prophylactic mastectomy. Because the presence of LCIS did not impact recurrence. The annual hazard rate of invasive cancer was 5.
Endocrine Therapy and Chemoprevention Another treatment option for patients with a diagnosis of LCIS is chemo- prevention with tamoxifen. Because LCIS poses no risk of regional metastasis. At the present time. Patients receiving raloxifene had a lower risk of thromboembolic events and cataracts.
In the group with LCIS in the lumpectomy specimen. Suspicious lesions are further evaluated with ultrasound. Use of screening ultrasound in patients with LCIS is being evaluated. A update. Patients found to have a suspicious abnormality on mammography or ultrasound undergo breast-conserving therapy with excision of the abnormality under needle localization.
They should also undergo annual bilateral diagnostic mammog- raphy. Raloxifene may be particularly beneficial to a postmenopausal woman with an intact uterus who also faces a risk of osteoporosis. Chapter 1 Noninvasive Breast Cancer 23 statistical difference in risk of other cancers. If they are found to have syn- chronous DCIS or invasive breast cancer. If not performed prior to obtain- ing the biopsy specimen.
The new mammograms are com- pared with previous images. Delaney G. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer.
All patients with LCIS are considered for clinical trials.
See a Problem?
Presence of lobular carcinoma in situ does not increase local recurrence in patients treated with breast-conserving therapy. Costantino J. Freedman GM. Taylor R. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. Ann Surg. Patients who undergo breast-conserving therapy for LCIS do not rou- tinely receive radiation therapy but are offered tamoxifen or raloxifene if they are suitable candidates for risk reduction with antiestrogen therapy.
Ciocca RM. After breast-conserving surgery. Redmond C. Sahin A. Am J Surg. Mathoulin-Pelissier S. El-Tamer M. Sherman ME. Chagpar A. Clinical decision-making in early breast cancer. Intraoperative margin assessment reduces reex- cision rates in patients with ductal carcinoma in situ treated with breast- conserving surgery. Pendas S. Carreon JD. Singletary SE. If necessary. Ann Surg Oncol. Bland KI. Recommended Readings Arpino G.
Cox CE. Gill M. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ. Fisher B. Brinton LA.
Breast ductal carcinoma in situ with microinvasion: Chun J. Yen T. Predictors of local recurrence after treatment of ductal carcinoma in situ: Following a bilat- eral prophylactic mastectomy with or without reconstruction. Lobular neoplasia on core-needle biopsy— clinical significance. Boyages J. Balch CM. Allred DC. N Engl J Med. Cox JM. Recent trends in breast cancer among younger women in the United States.
MacGrogan G. Mohsin SK. J Natl Cancer Inst.
Free The M.D. Anderson Surgical Oncology Handbook (5th Revised edition) pdf download
Wang M. Haagensen CD. Bijker N. Margolin FR. Tan LK.
Julien JP. Local excision alone without irradiation for ductal carcinoma in situ of the breast: Stough RG. Lobular neoplasia so-called lobular carci- noma in situ of the breast. Fisher ER. Westdahl PR. Land S. Cuzick J. Fowble B. Lagios MD.
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: Land SR. Prevention of invasive breast cancer in women with ductal carcinoma in situ: Hughes LL.
Semin Oncol. Tamoxifen for prevention of breast cancer: Breast Can- cer Res. Lattes R. Frequency of local recurrence following tylectomy and prognos- tic effect of nuclear grade on local recurrence. Holland R. Pagano I. Patient-reported symptoms and qual- ity of life during treatment with tamoxifen or raloxifene for breast cancer pre- vention: Klauber-DeMore N.
George WD. Page DL. Oncology Williston Park. Wickerham DL. Intraductal carcinoma duc- tal carcinoma in situ. Hollingsworth AB. Breast magnetic resonance imaging for preoperative locoregional staging. Wolmark N. Gill JK. Liberman L. J Clin Oncol. Vebeek AL.
Mamounas E. The association of mammographic density with ductal carcinoma in situ of the breast: Mammographically detected duct car- cinoma in situ. Costantino JP. Intraductal noninvasive breast cancer: Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK.
Kuerer HM. Maskarinec G. Tamoxifen in treatment of intraductal breast cancer: Jeruss JS. Sentinel lymph node biopsy: Beitsch PD. Lane N. Dignam J. Fentiman IS. Houghton J. Hendriks JH. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: Silverstein MJ. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. Graversen HP. Anderson BO. Full-field digital mammography compared to screen film mammography in the prevalent round of a population-based screening programme: Poller DN.
Klaasen H. Goldberg JI. Klingen TA. Breast Cancer Res Treat. Eur Radiol. Waisman JR. Cancer Prev Res Phila Pa. Daling JR. Cohlan BF. Nielsen M. Thomsen JL. Primdahl S. Vogel VG. Duct carcinoma in situ: Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast.
Toggle navigation. Subscribe Register Login. Advanced Search. If you're not a subscriber, you can: You can read the full text of this article if you: Your Name: Your Email:. Colleague's Email: Separate multiple e-mails with a ;. Thought you might appreciate this item s I saw at Annals of Surgery. Send a copy to your email. Some error has occurred while processing your request.
Please try after some time. October - Volume - Issue 4 - p The author declares no conflicts of interest. Annals of Surgery 4: Add Item s to:The dynamic nature of the field of surgical oncology will demand that we continue to revise and update its con- tents; it is exciting to know that some of you reading this will contribute to future editions! The incidence of microinvasion in DCIS varies according to the size and extent of the index lesion.
Practicing surgeons will find it an excellent compact reference for uncommon malignancies. Genitourinary Cancer Jose A. Suspicious lesions are further evaluated with ultrasound. Numerical values ranging from 1 best prognosis to 3 worst prognosis are assigned for each of the four predictors. Andtbacka, Emily K. Melanoma 85 Joshua M. These studies have examined sequential and concurrent taxane administration and taxanes as a substitute for an anthracycline.
- ALGORITHMS 4TH EDITION ROBERT SEDGEWICK PDF
- RUBY ON RAILS TUTORIAL 2ND EDITION PDF
- MACHINERY HANDBOOK 29TH EDITION PDF
- PROGRAMMING RUBY 1.9 & 2.0 4TH EDITION PDF
- HUMAN RESOURCE MANAGEMENT GARY DESSLER 11TH EDITION PDF
- FUNDAMENTALS OF ELECTRIC CIRCUITS 4TH EDITION SOLUTION PDF
- SOCIAL PSYCHOLOGY ARONSON 7TH EDITION PDF
- TEXTBOOK OF DIABETES 4TH EDITION PDF
- EMPIRE ARMY BOOK 8TH EDITION PDF
- HINDI TYPING LEARNING BOOK
- PRO MYSQL EBOOK
- SECRET SEVEN SERIES EBOOK
- ADOBE ILLUSTRATOR CS4 BOOK
- RTE APPLICATION FORM 2016-17 PDF